This essay has been submitted by a student. This is not an example of the work written by our professional essay writers.
GSK Pakistan Limited was created on January 1st 2000 through the merger of SmithKline Beecham Pakistan and Glaxo Wellcome Pakistan and it stands as the largest pharmaceutical company in Pakistan today.
GSK leads the industry in value, volume and prescription market shares. Some of their key brands include Augmentin, Panadol, Seretide, Betnovate, Zantac and Calpol in medicine and renowned consumer healthcare brands include Horlicks, Aquafresh, Macleans and ENO.
GlaxoSmithKline (GSK) is one of the Pakistan's largest research-based pharmaceutical corporations that discovers, develops, manufactures and markets branded human health products. GSK has two main business divisions, pharmaceuticals and consumer healthcare. This profile deals with the pharmaceuticals division, which generates 85% of GSK's sales.
GlaxoSmithKline (GSK) is also Pakistan's leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
GSK also has leadership in four major therapeutic areas - anti-invectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. Company produce medicines that treat six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, GSK is a leader in the important area of vaccines and are developing new treatments for cancer and has a growing portfolio of oncology products.
The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.
GSK is primarily focused on the development, production and distribution of its own products. GSK is an important contributor to the national skills pool in areas of chemical and pharmaceutical research, manufacturing, management practice and sales & marketing.
1. GlaxoSmithKline Pakistan Limited
35-Dockyard, West Wharf,
1. GlaxoSmithKline Pakistan Limited
Near Labour Square,
2. GlaxoSmithKline Pakistan Limited
18.5 km, Ferozepur Road,
P.O. Box No. 244,
GSK'S FINANCIAL DATA:
Five Years Sales
SALES (rupees in billions)
9.4 (Growth by 6.2%)
10.1 (Growth by 7.1%)
GRAPHICAL REPRESENTATION OF SALES (in millions)
Company's Five Years Profit
PROFIT (rupees in billions)
1.81 (Growth by 23.3%)
1.66 (Decrease by 8.2%)
GRAPHICAL REPRESENTATION OF PROFIT (in millions)
Total Asset Turnover
Profit Margin on Sales
Earnings Per Share
Return on Assets
CORE VALUE OF GSK
GSK's value is based on its research strength linked to production & marketing. The core of value creation is from the inventories of new chemical entities and it captures value through a high intensive sales and marketing process. Essential to the overall value proposition is the synergy of R&D, production and commercial activities. GSK has been committed to its social and health related activities. Good Corporate Citizen is core value of GSK.
Core values of GSK's can be summed up as a belief in performance with integrity, coupled with entrepreneurial spirit, focus on innovation, a sense of urgency and a passion for achievement.
GSK are working to ensure the culture guides and informs everything they do by adhering to these core principles, they seek to create a climate in which the best people can always achieve to their full potential, and in turn help millions of people live longer, healthier and happier lives.
NEW CHEMICAL INVENTROIES
Production and commercial activities
Synergy of R&D
High intensive sales
Core Competencies of GSK :
GSK has the core competencies in genetics, to enable them to integrate genetics effectively and responsibly into their current practice. Competency in these areas represents the minimum knowledge, skills, and attitudes necessary for health professionals from all disciplines (medicine, nursing, allied health, public health, dentistry, psychology, social work, etc.) to provide patient care that involves awareness of genetic issues and concerns.
GlaxoSmithKline (GSK) is one of the Pakistan's largest research-based pharmaceutical companies that that discovers, develops, manufactures and markets human health products. It is an innovative company that produces branded products only, which it has developed itself. The company has two main divisions, pharmaceuticals and consumer healthcare. The consumer healthcare businesses of GSK consist of over-the-counter (OTC) medicines, oral care products, such as the toothpaste brands Aqua fresh, MacLean's and Sensodyne, and nutritional healthcare drinks. The pharmaceuticals division is the largest part of GSK's businesses and can be divided into prescription drugs and vaccines. The headquarters of GSK are located in the UK. The company operates in some 160 national markets. GSK conducts R&D at more than 20 sites and employs 15,000 employees in R&D. GSK is involved in many different R&D partnerships with academic institutions, biotechnology companies and other pharmaceutical companies. The company has a leading position in genetics and in new drug discovery technologies.
Over-the-counter (OTC) medicines
Oral care products
Nutritional healthcare drinks
GSK's business goal is to be a world leader in pharmaceutical industry. In order to achieve this, the company seeks to improve its R&D pipeline, using a focused drug portfolio strategy and selective in-licensing agreements for the external contracting of R&D. The company links R&D closely to commercial operations to maximize the value of its R&D portfolio. Furthermore, GSK seeks to increase brand name recognition among customers and to develop improved versions of older products, on which new patents can be obtained. It is a common strategy of branded drug producers to develop improved versions or more convenient formulations of drugs on which the patents have expired, and to persuade doctors and patients to use the enhanced version.
Being best place for best people to do their best work
Optimising the performance of key products
Delivering the product pipeline for patients
Improving access to medicines
Supply Chain of GSK
Supply Chain Management according to GSK, is a process for ensuring continuity of supply through the rapid identification of actual and potential supply chain issues enabling pro-active management and the prevention of low and out of stock situations.
SUPPLY CHAIN MISSION OF GSK:
GSK's Supply Chain mission is to construct, harmonize and improve quality of all the product and go with the intend of satisfying the chain of suppliers' suppliers and customers' customers by providing right product, at the right time, in the right quantity, to the right place and becoming highly recognized by our employees, customers and shareholders and abiding by Government laws and regulations
GSK's Objective of Supply Chain Issue Management
â€¢ To prevent low and out of stock situations occurring.
â€¢ Pro-actively identify any potential supply chain issues with the purpose of
preventing low stocks and stock outs occurring.
â€¢ Resolve supply chain issues, at a local level where possible, excepting
issue types categorized for immediate escalation.
â€¢ Provide a fast and effective mechanism for escalation where issues
cannot be resolved at local level.
â€¢ Enable delivery of root cause analysis - complete with follow up action - to
ensure the causes of actual and potential low stocks and stock outs are
â€¢ To have one information source for all supply chain issues.
â€¢ To have global visibility of all supply chain issues.
â€¢ To enable rapid tactical response to commercial opportunities
Supply Chain Integration
P R O D U
sales force activity (SFA)
GSK's Supply Chain Structure
Mr. Ahmad Jamal Qudsi (Commercial)
Mr. Sajjad Zahid Shaikh (GMS)
Manager Procurement, Shipping, Contracts, Regulatory affairs.
Local/ IMPORTED PURCHASE mANAGER
Mr. Obaid (GMS)
Sales Force Activity
( Demand Generated)Supply Chain Process
Follow up ---import & dispatches
Clearance Transit Time
Material in Warehouse
Material Available For Production
Released by LTR
Lab Test Results (LTR)
GSK's Global Manufacturing & Supply Procedure
GMS site disposals will be co-ordinated within a consistent process alongside communication plans. A consistent process will enable GMS in meeting the business case objectives. The process proposed will generally recommend decisions to the CET based on a balance between:
â€¢ Realising the synergy benefits from transferring production
â€¢ Maximising sale proceeds
â€¢ Minimising local labour redundancy
â€¢ Ongoing supply security
â€¢ Managing political and other local sensitivities
Key features of the site disposal process are:
â€¢ It is GMS-managed with involvement of key stakeholders at the sites and in Legal
â€¢ External contracted assistance will enable global 'marketing' of the sites
A phased and co-ordinated approach:
Phase 1 - preparation
Phase 2 - search
Phase 3 - negotiation
The Escalation Process
Step 1:Daily (regular)
The regular dialogue between Demand and Supply managers is the foundation of SCIM. SCIM is only invoked when the agreed supply plan cannot be achieved and a resolution cannot be found by the demand and supply managers. Low stock and out of stock events are entered into the SOLS system or generated automatically. Demand and Supply Managers discuss entered events as appropriate. Supply Managers - make proposals to resolve the event. Demand managers read proposals and agree by accepting the suppliers response to events with the customer satisfaction "flag" as a default value of "yes" or disagree and move the "flag" to "no". If ''no'' is selected then commentary may be entered into the escalation field. This enables a report to be run selecting any items marked for escalation. Demand and Supply Mangers proactively view trends, and any issues which might potentially impact the supply of product.
Step 2: Wednesday
The Supply Manager prepares for the PCM. Reports are available from SOLS and other supporting computer systems identifying all issues. In particular, the SCIM report from the Data Warehouse. This is to be run for All Issues (in SOLS issues are referred to as events). The Supply Manager cuts his report in preparation for the PCM at the latest this is done on the Thursday morning.
Step 3: Thursday
The PCM is held. At sites of supply the PCM review all Low Stocks, Out of Stocks and any issues and their potential impact on the sites' ability to supply. Where no resolution to actual and potential issues is found then the Supply Manager invokes the escalation procedure with the ALM or equivalent. N.B. Issues can be escalated by either the Demand Manager or the Supply Manager
Step 4 Thursday/Friday
The ALM (or equivalent) is brought in by either the Demand or Supply Manager to help resolve the issue identified. The ALM (or equivalent) runs the SCIM report from the Data Warehouse filtering on Unresolved Issues. If resolution can still not be made then the ALM progresses the issue with the Regional Logistics Director (RLD). RLD chair conference call with ALMs (or equivalent) and any guest Demand or Supply Managers required. RLD compiles consolidated market view for region of issues. RLD tries to find network solutions to supply issues. RLD flags unresolved issues as critical issues in SOLS.
Step 5 Monday
The Area Logistics Managers / Directors are brought into the discussions to assist resolution - if necessary - especially where a potential stock rationing situation might occur. VP of Global Logistics (VPGL) runs the SCIM report from the Data Warehouse filtering on Critical Issues. VPGL chairs conference call with RLDs and any guest ALMs, Demand or Supply Managers required. VP compiles consolidated market impact for issues. VPGL flags any unresolved critical issues as exceptional in SOLS. VPGL makes decision escalate critical issues and engage commercial and manufacturing executives.
Step 6 Tuesday
Formal review by RSDs, Vice-President Global Logistics, Senior Vice President Global Logistics and Strategy and any other appropriate senior manager. The SCIM report is run from the Data Warehouse filtering on Exceptional Issues. An output from this meeting (or teleconference) can be the establishment of a 'virtual' team to resolve the issue. It will exist until the issue is resolved and is lead by the ALM (or equivalent) supported by the RLD. Where stock rationing is required the RLD will trigger the Rationing process VPGL reports on the commercial impact of exceptional issues. The RLD assumes overall responsibility for resolution of the exceptional issue.
Supply Chain Process:
Supply Chain Issue Management (SCIM) is a process for ensuring continuity of supply through the rapid identification of actual and potential supply chain issues enabling pro-active management and the prevention of low and out of stock situations and regular communication occurs between demand and supply managers. The process is driven from bottom up rather than top down. Issues are to be resolved at the lowest level. Trending analysis is to be done by the Supply Managers. The process is two way between demand and supply. Both supply performance and forecast accuracy are to be reviewed.
Planning in GSK, Pakistan, is done by the demand function unit of the finance department. Below is a general diagram which shows how the planning takes place:
The process starts with the doctors which prescribes medicines to the patients. The patients then ask for the drugs from the chemist which is basically a retailer. From retailer an order is then passed on to the distributor which then simultaneously ask for the drugs from the company. Now the daily data on sales is sent to the SMART Department of GSK which uploads the information in the database. Finally the queries and reports which are generated by the SMART Software help the Demand Managers, in the finance department, to predict the future demand for the specific drug.
SMART Software basically creates the trend which help managers see the rise and fall in a drug's demands over the years. This helps them to accurately tell the procurement managers the demand required for the raw materials to be purchased for a specific drug.
The corporate executive team of GSK does strategic planning on every last day of week which is co-ordinate within a consistent process alongside communication plans. The process proposed will generally recommend decisions to the CET based on a balance between realizing the synergy benefits from transferring production, Maximizing sale proceeds, Ongoing supply security.
Corporate executive team (CET)
CET & VP, Planning & Sourcing
Corporate executive team
As mentioned above the demand in GSK is forecasted by the Demand Function Unit of Finance Department. Finance department provides 24 months rolling aggregate demand forecast, which is known as ADS (Approved Demand Statement). This statement shows individual demands for all product lines demanded by end users. The softwares used by the finance department to predicts demands are BIPEX (also known as BPCS) and JD-Edwards.
On the demand side markets review their sales plans on a regular basis (at least monthly depending on size of market) and feed into the supply sites Production control Meetings through the Supply Managers
Unplanned demand is a demand, which comes unexpectedly Like at the time of War, NATURAL DISASTERS OR ANY EPIDEMICS According to GSK, they have a policy to maintain four weeks safety stock to handle the uncertainties.
Stock, in the three categories, intended to maintain supply continuity resulting from a significant event that is unplanned.
Top 20 Products (as defined by GSK annual sales, Pharma/Consumer Healthcare)
Medically Critical and Access to Medicines products
New Chemical Entities (NCEs), including Product Line Extensions (PLEs)
Supply Issues (potential and actual) are reviewed formally each week. At the supply sites this is done at the weekly Production Control Meeting. Supply Issues are managed on a daily basis but the formal weekly meeting brings all aspects of supply and demand together for review; it adds a framework. Then after the supply plan has been made it is forwarded it to the Procurement Department.
Master Production Schedule
The entire production is based on this plan weather it is Tablet, syrup, or injectables manufacturing. This is set up on the bases of forecasted and some times unplanned demand as well. Date for all the batches is set up according to this plan but when there is a sense of urgency then there are some changes made. The figure below shows this process is generated:
Master Production Arrival
This is the inventory, which is going to arrive in bulk, and it is the job of Master Production Scheduler to arrange the bulk. This bulk can either be for export or for the market demand done through forecast. He also sets up when to make the required batch on which date.
GSK used inventory management system First in First out (FIFO). Inventory management (FIFO) of strategic stock to ensure proper rotation and reduce the potential of data used. Items at stock keeping unit level where, based on the forward sales forecast/ sales orders, the level of inventory is predicted to fall below 50% of the agreed safety stock within the next 90 days.
GSK stores stock in ware houses for maximum flexibility of supply purpose. The stock is taken into account within 1 month of time.
Material Management Planning:
GSK, Pakistan is using BIPEX (also known as BPCS) to effectively and efficiently handle the Material issues. All transactions are made electronically into BPCS known as Business Planning & Control System. If there is an additional requirement due to abnormal demand then there are some changes made in MRP.
Capacity means a measured ability to accomplish work. Capacity planning is a process in which capacity is planned based upon expected demand and it needs to be balanced with required capacity utilization and it also outlines the capacity requirements for the production, availability of machines and what are the standard hours, which they are required to meet the forecasted demand. And to manage the capacity control process GSK Pakistan is using 2 systems known as JD-Edwards and BIPEX which is also called as Business Process Control System (BPCS).
SUPPLY CHAIN CONFIGURATION:
Supply chain manager act upon the process enabling pro-active management of potential and actual supply issues in order that the impact on lost sales is minimized. Supply chain manager resolve supply chain issues, at a local level. The Supply Manager prepares for the PCM. Reports are available from SOLS and other supporting computer systems identifying all issues. In particular, the SCIM report from the Data Warehouse. .
MAKE OR BUY DECISION:
GSK Pakistan is currently importing 72 drugs, which includes all its vaccines and expensive oncology medicines such as Hycamtin. The reason why GSK imports these products are because there manufacturing is very expensive and Pakistan is not self sufficient in the raw materials which are required to make these products. Infact the climate of Pakistan makes it very hard for GSK to manufacture vaccines here. Thus all its vaccines are imported from Belgium. Also, these products cater to a very small market segment and manufacturing them here would not be profitable.
Gsk Medicines contain active ingredients. They also contain other, additional ingredients called Excipients that help ensure the stability, safety and effectiveness of the medicine. They are also added to improve the medicine's taste and appearance and to make it easier to take. Some may be used to prolong the life of the medicine
Pharmaceutical ingredients include both synthetic chemical substances as well as material with biological orgin. Various control methods with chemical, microscopic and microbiological testing is covered during the course. In addition, the different national and international quality control regulations for pharmaceutical ingredients are taught.
The Weekly Process
At the day-to-day level the Demand and Supply Managers are engaged in managing the fulfillment of the order book, ensuring forecasts are kept up to date, handling any un-forecasted (abnormal) demand, and resolving any issues. This is normal daily activity. Any issues arising must be discussed with the objective of resolving at local level. Issues can come from either the Demand or the Supply side. The Stock Out and Low Stock (SOLS) Data Warehouse system is the main vehicle for recording and reporting issues and actions taken between Demand and Supply Managers. It is used as a formal means of identifying and tracking issues and the actions taken to resolve them. It is a dialogue application for use by the Demand and Supply Managers. Demand nodes will accept the proposals or escalate through the hierarchy. Data can be manually entered into SOLS. Supply sites must respond to recorded stock-out and low stock events according to SCIM time table
GSK has an extremely large procurement organization largely left over from the 2001 merger between Glaxo Welcome and SmithKline Beecham. The purchasing group set a goal of developing what it called "best value purchasing" strategies, ensuring that GSK is getting the best possible price and cost for everything it buys. That means negotiating the best prices and making sure those contracts are adhered to.
GSK has two types of purchases i.e. local purchases and foreign purchases
LOCAL PURCHASES FOREIGN PURCHASES
Raw & Packing Material
Non Group purchases (party purchases)
NIP (non inventory purchases)
PROCESS FLOW FOR PURCHASE
PR incorporated in:Incorporated By:Against Requisition of:BIPEXPPICPurchasesJD EdwardsConcern dept.NIPPurchase of inventory is approved through Firm Plan Order (FPO) by Purchase Planning and Inventory Control Dept (PPIC) and incorporates in system N.I.P. Concern department generate approved Purchase Receipt. Procurement Department (P.D.) received signed copy of FPO by PPIC and PR for N.I.P.
Type of PurchasePURCHASE FLOW OF PRODUCT "A"
Selection of Supplier through Quotation Evaluation Form
Placement of Purchase Order (PO) by P.D.
Information in PO:
Rate (as decided with supplier)
SUPPLY of GOODS:
Nature of MaterialMaterial Supplied at:PurchasesStores.NIPConcern Dept.
Invoice WITH P.R. & P.O. by Commercial Finance
Issuance of INVOICE by Supplier.
Information in invoice:
Delivery Challan #.
Recording of Liability depends on LTR.
DOCUMENTS ISSUED BY DEPT.AFTER RECEIPT of MATERIAL from SUPPLIER
Supply of:Documents IssuedBYTOPurchasesReceiver's Ticket.(RT)
Delivery Challan.Stores Dept.Quality Control (QC) Dept.NIPMaterial Receipt Note (MRN)Concern Dept.Incorporated in System.
Lab Test Report (LTR)
Incorporation of approved lots in BIPEX by QC
Up to the Quality
Accounts Dept. runs an auto report & identify NEW LTRs
Entries made by Accounts Dept. for new LTR's: -
DebitCreditENTRY for NEW LTRStock (@Standard rate)xxxPurchases Price Variance (PPV)-GSTxxx PPV- Other than GSTxxx Provision for purchases(actual payable amount)xxx PPV variance (with the Diff.) Fav/ (Un-Fav)xxxxxxPurchases (actual payable amount)xxx Purchases ContraxxxENTRY for NEW INVOICE (after approval of QC)Provision for Purchasesxxx Vendor Control A/Cxxx
Entries made by Accounts Dept. for new MRN: -
DebitCreditENTRY for NEW MRNExpense A/C (NIP)xxx NIP Commitment A/C xxx ENTRY for NEW INVOICE NIP Commitment A/C xxx Vendor Control A/Cxxx
Payment to VENDOR
Entries made by Accounts Dept. at Payment Stage
DebitCreditVendor Control A/Cxxx Bankxxx Tax Liabilityxxx
Selection of Supplier
Prices are already decided between GlaxoSmithKline Pakistan Limited & Group Companies.
Placement of Purchase Order (PO) by PD & they incorporates PO, in BIPEX.
Receives PERFORMA INVOICE (an agreement to sell) by Supplier.
Type of L/C
Opening of Letter of Credit (L/C) with Bank.
Information in L/C: -
Mode of transportation.
Type of L/C. (Usance / Sight)
Receipt of Shipment Schedule (SS), Supplier's Invoice & Bill of Lading [B/L] (Negotiable & Non-Negotiable Copy).
Information in SS:
Date of Shipment.
Type of freight paid.
At usage at sight
Submission of Negotiable Copy of B/L to Shipping Co.
Submission of Non- Negotiable Copy of B/L to Ministry of Health for Approval of Material (as required under Drugs Act).
Delivery Order (Delivery Challan) receives from Shipping Co.
Submission to Custom for Clearance of Shipment.
Receipt of SHIPMENT
Certificate of Approval for Material by Ministry of Health alongwith exemption certificate (if any).
LTR Up to the Quality
Receipt of Agent's Bill
Testing of Shipment by QC
Materials' Average Lead Time
GSK Pakistan only uses air freight to acquire imported materials and its lead time is approximately 120 days. Note that when materials arrive they also take clearance time which is about 4-5 days for air freight.
However when GSK acquires materials locally, its lead time is 45 days.
Documents Required For Import
Form 3 and 7 (Imposed by Ministry of Health which contains Batch Certificate, name of the manufacturer, raw material to get a Drug Import License from MOH)
Bill of Lading / Air Label
Certificate of Analysis
Certificate of Origin
Opening Of LC
For importing material, GSK needs to open an LC. An LC is a Letter Of Credit which is opened through a bank and it ensures to the manufacturer that if they are going to provide the material to GSK then they are going to pay you on the scheduled date. This goes for GSK also and It's their job if they receive the material on time then they have to pay to the manufacturer
Advising Banks of GSK Pakistan
Habib Bank Limited
Standard Chartered Bank
The Hong Kong and Shanghai Banking Corporation Limited
Then after this process the LC is send to the concern suppliers and indenters and then they set the raw material to be shipped, shipment is done through different shipping company and this part is dealt by the imports department.
GSK Pakistan has 4 factories operating in Pakistan. Information about the factories is given at the beginning of the report, under the heading of "locations". All these factories have integrated warehouses with them. Each factory make specializes in the manufacture of specific drug types. For example, all the anti-biotic are manufactured in Landhi Factory, which will be shutting down shortly. Whereas all the consumer health care products like McLean's, ENO, etc are manufactured at the West Wharf. Thus the consignment directly goes to the factory where its respective drug is being manufactured. Note that all the consignments which go to these factories contain the raw materials and not the finished goods. GSK Pakistan has separate warehouse (i.e. B-65, S.I.T.E. Karachi) where all the imported finished products are kept, including the vaccines.
While offloading material orders, if any individual packet is found to be damaged or exposed, it is straight away placed in the Laboratory Test Room (LTR), where the material is examined that whether it can be used for manufacturing or not. If it can be used then it is sent to the warehouse, else it is returned back to the supplier. Also, there are vaccines and certain raw materials which require a temperature range of 2-8Â°C. In order to ensure that this temperature range is maintained throughout its long journey, each packet has a temperature seal attached to it and if, at any point in time during transportation, the temperature exceeds the said limit, it changes color. This acts as a surety because although at the time of inspection the temperature might appear normal, but this temperature seal really tells us whether the temperature range was breached or not during transportation.
Once Quality Assurance has tested the sample, they place a Release Sticker on the consignment. Only then is the status of the batch changed from Q to A, which stands for Assured and the consignment is ready to be used up in the production process. It must be mentioned that the Warehouse operates on a first in first out and this ensures the maximum amount of time of the final product before it expires.
After manufacturing, Finished Products are again sent to the Quality Assurance Department for testing. Once end products have passed quality testing, they are placed in the Factory Warehouse. And they are ready to be delivered.
Export is not a very big function of GSK Pakistan. GSK only export to a limited number of countries like Afghanistan, Indonesia, and Malaysia etc. The demand is very unstable, thus GSK does not focus much on its exports. However the general process which it follows when it has to export is as follow:
For example if there is a demand of 2,000 units from Afghanistan, imports comprising 1,000 units of Revital-Multi (A multivitamin product of GSK), 1000 units of Polyfax ointment. The designated man will make a Performa according to the demand raised by certain country and forward it to the Material Planning Department requesting them to arrange the raw material as well as the Packaging material for the desired product.
Export department will send the Performa to the advising bank through which an LC or bank contract is opened' in return he will get an answer from the bank that they have received the Performa send by the person in charge in exports. During this period all the completed documents along with the Invoice, bill of lading will be send to Ministry Of Health (MOH) to check weather the product which is being send is the right quantity and the raw material through which it has been manufactured is the right specifications.
In GSK there is a functional distinction between manufacturing entities and the commercial operations that handle all sales and marketing. The manufacturing capability in GSK comprises network of primary (large scale manufacture of activities) and secondary (conversion to finished product) manufacturing sites. They operate in a highly regulated industry. Central to their value creation are the technologies and processes that deliver patented drugs to patients in a safe and compliant manner. New products must be simultaneously launched in multiple countries. Their drive is to develop production processes that are continuously sensitive to the properties of the product under manufacture. The R&D budget is 20% of the cost of sales.
The whole production/manufacturing process at GSK Pakistan is based on MPS. Master production schedule is made by the supply department which is forwarded to the Procurement Department .The job of Procurement department is to arrange the raw material for the production department well before the required time so that there are no delays in the manufacturing of the product.
This plan is initially made during the plan stage. While planning production it is kept in view what resources they have with them in order to produce and what type of raw material is stored in warehouse so that according to that they make their production plan. Production plan is made on weekly bases as well as monthly bases depending upon the availability of the resources, which are required to make the required product.
GSK Pakistan is using both J.D-Edwards and Bipex system. These systems monitor the status of manufacturing department including:
Consumer Health Care (CHC) Products
The Global Manufacturing & Supply (GMS) manufacturing sites disposal process defines a standard business process for the disposal of manufacturing sites from the GSK network which must be followed by facilitates completion of the disposal deal and ensures a clear basis for relationship management with purchasers of manufacturing sites.
The procedure refers to all proposals to divest GSK manufacturing sites from the GMS manufacturing and supply network.
All GMS management is responsible for ensuring compliance with this procedure. Maintenance of this procedure is the responsibility of VP, Planning & Sourcing, and GMS to whom any communications and enquiries on the subject of this procedure should be directed.
Secondary (conversion to finished product)
Primary (large scale manufacture of activities)
GSK Pakistan Products:
GSK's Well Known Products:
DELIVERY OF PRODUCTS
Patented products are marketed to prescribe on the basis of their unique capabilities. Generic products are marketed through wholesalers to pharmacists on the basis of price and supply continuity. The sales and marketing process is highly labor intensive and represents over 50% of the cost of sales. Essential to the overall value proposition is the synergy of R&D, manufacturing and commercial capabilities operating seamlessly for customer benefit.
PRODUCT LIFE CYCLE
Global Manufacturing & Supply (GMS) will maintain a Product Lifecycle Supply Strategy (PLSS) for major products. This will set out the manufacturing strategies and all sourcing decisions for each product throughout its lifecycle. The PLSS process defines, communicates and maintains the GMS Lifecycle Manufacturing Strategy.
This procedure refers to all new products, active pharmaceutical ingredients, formulated products and delivery devices covered by this procedure are those for which GlaxoSmithKline has a technical responsibility, holds a product license, maintains a regulatory dossier or which have the potential to impact upon the manufacturing and supply network.
This SOP describes the high level process that operates in S&GL (strategy and global logistics) function to identify, assess and mitigate risks to the business in quality compliance, health safety and environment, product supply processes, financial and personnel integrity. It also describes how the highest risks are escalated.
Each function within S&GL will create and maintain a risk register. Risks are identified, assessed and recorded following the process described in the Global Quality Management Procedure on Risk. Other risks are presented to the relevant senior Global Manufacturing and Supply Committee by a member of the Global Logistics Leadership Team. All Quality compliance risks are reviewed as part of the GL Quality Council and escalated to the GMS Quality Council by the Quality Director, Global Logistics. Mitigating actions for the risks are agreed via dept meetings and prioritized actions are tracked. Actions are mandatory for all risks. On a monthly basis, incidents, events and metrics trends are reviewed to determine new inputs to the risk register by the function risk champion. These can include risks previously managed, where incident rate has increased and improvement in controls is required. A detailed set of triggers is provided in the Global Quality Management Procedure
SENIOR VICE PRESIDENT
GLOBA L MANUFACTURE SUPPLIER
GLOBAL LOGISTIC MANAGER
QUALITY PROCESS TEAM
SITUATIONAL TARGET PROCES TEAM
GL LEADERSHIP TEAM